Skip to main content

Qiagen Buys Xeragon for $8M to Bolster Oligo Business

NEW YORK, April 18 - Qiagen said today it has bought Xeragon for about $8 million as part of its goal of expanding its oligonucleotide business.

Qiagen paid for the deal by issuing 564,000 shares in exchange for all of the outstanding capital stock of Xeragon. Qiagen said it may issue an additional payment of up to $1.2 million in cash or stock if certain performance targets are met by next December.

Xeragon's 2003 product line is expected to contribute $4 million in net sales and $1 million in net income to Qiagen, the Dutch genomics firm said.

Xeragon, based in Huntsville, Ala., has a staff of 10.

The Scan

Rise of B.1.617.2 in the UK

According to the Guardian, UK officials expect the B.1.617.2 variant to soon be the dominant version of SARS-CoV-2 there.

Anne Schuchat to Retire

Anne Schuchat is retiring after more than 30 years at the US Centers for Disease Control and Prevention, Politico reports.

US to Share More Vaccines

CNN reports that the US will share 20 million doses of the Moderna, Pfizer, and Johnson & Johnson SARS-CoV-2 vaccines with other countries.

PNAS Papers on Gene Therapy Platform, Aspergillus Metabolome, Undernutrition Model Microbiome

In PNAS this week: approach to deliver protein-based treatments to cells, pan-secondary metabolome of Aspergillus, and more.